Dr. Reddy’s Laboratories Ltd $RDY Shares Sold by Renaissance Technologies LLC

Posted by Brian Himes on Jul 26th, 2026

Renaissance Technologies LLC cut its holdings in Dr. Reddy’s Laboratories Ltd (NYSE:RDY – Free Report) by 4.8% in the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,859,728 shares of the company’s stock after selling 395,400 shares during the quarter. Renaissance Technologies LLC’s holdings in Dr. Reddy’s Laboratories were worth $108,857,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in RDY. Robeco Institutional Asset Management B.V. grew its stake in shares of Dr. Reddy’s Laboratories by 0.5% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 13,154,524 shares of the company’s stock worth $184,690,000 after acquiring an additional 70,018 shares during the last quarter. Morgan Stanley increased its holdings in shares of Dr. Reddy’s Laboratories by 41.2% during the fourth quarter. Morgan Stanley now owns 8,926,051 shares of the company’s stock valued at $125,322,000 after acquiring an additional 2,603,897 shares in the last quarter. Aikya Investment Management Ltd raised its position in shares of Dr. Reddy’s Laboratories by 9.3% in the 4th quarter. Aikya Investment Management Ltd now owns 7,338,525 shares of the company’s stock valued at $103,033,000 after purchasing an additional 623,518 shares during the last quarter. BNP Paribas Financial Markets raised its position in shares of Dr. Reddy’s Laboratories by 3.7% in the 4th quarter. BNP Paribas Financial Markets now owns 4,152,566 shares of the company’s stock valued at $58,302,000 after purchasing an additional 149,384 shares during the last quarter. Finally, Bessemer Group Inc. boosted its stake in Dr. Reddy’s Laboratories by 28.4% in the 1st quarter. Bessemer Group Inc. now owns 1,823,285 shares of the company’s stock worth $25,253,000 after purchasing an additional 403,219 shares in the last quarter. 3.85% of the stock is currently owned by hedge funds and other institutional investors.

Dr. Reddy’s Laboratories Stock Down 0.2%

Shares of RDY stock opened at $11.78 on Friday. The stock’s 50-day simple moving average is $13.49 and its 200-day simple moving average is $13.63. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.34 and a current ratio of 1.90. The firm has a market capitalization of $9.83 billion, a PE ratio of 26.76, a P/E/G ratio of 2.17 and a beta of 0.25. Dr. Reddy’s Laboratories Ltd has a fifty-two week low of $11.36 and a fifty-two week high of $15.67.

Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) last announced its quarterly earnings data on Tuesday, July 21st. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). Dr. Reddy’s Laboratories had a return on equity of 9.49% and a net margin of 10.15%.The firm had revenue of $850.26 million during the quarter, compared to analysts’ expectations of $850.56 million. Equities analysts expect that Dr. Reddy’s Laboratories Ltd will post 0.47 earnings per share for the current year.

Analyst Ratings Changes

RDY has been the topic of several research analyst reports. Wall Street Zen downgraded shares of Dr. Reddy’s Laboratories from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings cut shares of Dr. Reddy’s Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a report on Thursday. Finally, The Goldman Sachs Group downgraded shares of Dr. Reddy’s Laboratories from a “neutral” rating to a “sell” rating in a research note on Thursday, April 23rd. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce”.

Get Our Latest Stock Analysis on RDY

Dr. Reddy’s Laboratories Company Profile

(Free Report)

Dr. Reddy’s Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company’s core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development.